Workflow
Genomics target discovery
icon
Search documents
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
Globenewswire· 2025-08-27 12:30
THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on Wednesday, September 3 at 1:45 p.m. ET and at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8 at 3:00 p.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company’s website at https://investors.lexpharm ...
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globenewswire· 2025-07-31 12:00
THE WOODLANDS, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Nasdaq's listing qualifications staff has determined that the closing bid price of the Company's common stock has been at $1.00 per share or greater for ten consecutive business days and that, accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). This update was previously disclosed in the Company's Current Report on Form 8-K filed on July 28, 2025. For In ...
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
Globenewswire· 2025-07-23 12:00
THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at ht ...
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
Globenewswire· 2025-05-06 20:30
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/. About Lexicon Pharmaceu ...
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Globenewswire· 2025-05-06 12:00
Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through the Genome5000™ program, ...
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
Globenewswire· 2025-03-07 13:30
Group 1 - Lexicon Pharmaceuticals will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 on March 12 at 10:00 a.m. ET [1] - The event will be accessible live and as a replay on the company's website [1] Group 2 - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The company utilizes the Genome5000™ program to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential [2] - Lexicon has advanced multiple medicines to market and has a pipeline of drug candidates in various stages of development for conditions such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2]